Company Overview
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -22.95% |
| 6 Months: | -30.75% |
| 3 Months: | -3.29% |
| 1 Month: | -8.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 68.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TNYA Tenaya Therapeutics, Inc. PHARMA | 0.66 | -1.29 | $147.99M | 0.00% | -70.98% | -121.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 225.00K | 1.11M |
| Operating Income | - | -8.87M | -10.45M | -13.11M | -15.24M | -18.30M | -31.15M | -28.62M | -31.30M | -33.72M | -35.10M | -30.92M | -33.76M | -30.82M | -26.71M | -27.54M | -24.08M | -20.94M | -20.07M | -44.09M |
| Net Income | -9.05M | -8.73M | -10.29M | -13.10M | -15.21M | -18.26M | -31.06M | -28.40M | -30.70M | -31.74M | -33.27M | -29.14M | -32.23M | -29.43M | -25.63M | -26.86M | -23.28M | -20.27M | -19.27M | -43.39M |
| Diluted EPS | - | - | - | - | - | -0.68 | -0.75 | -0.69 | -0.74 | -0.43 | -0.45 | -0.39 | -0.40 | -0.34 | -0.30 | -0.24 | -0.14 | -0.12 | -0.09 | -0.20 |
| R&D Expense | - | 6.96M | 8.48M | 9.59M | 10.91M | 12.94M | 24.16M | 20.88M | 23.76M | 25.61M | 26.48M | 23.09M | 25.05M | 22.65M | 20.35M | 21.08M | 17.37M | 15.36M | 14.84M | 16.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -38.91M | -72.81M | -125.62M | -131.19M | -115.95M | -93.33M |
| Net Income | -38.40M | -72.72M | -123.67M | -124.08M | -111.13M | -90.60M |
| Diluted EPS | - | -4.10 | -2.76 | -1.68 | -1.31 | -0.59 |
| R&D Expense | 31.10M | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 148.16M | 314.19M | 278.94M | 170.51M | 119.94M | 146.92M |
| Total Equity | -43.74M | -81.31M | 278.53M | 243.38M | 139.42M | 92.85M | 123.27M |
| Cash & Equivalents | - | 128.53M | 38.13M | 95.27M | 45.68M | 4.32M | 100.55M |
| Total Liabilities | - | 8.72M | 35.66M | 35.57M | 31.09M | 27.09M | 23.66M |
| Current Liabilities | - | 5.04M | 21.77M | 24.25M | 22.73M | 15.97M | 15.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.45M | -60.81M | -104.42M | -102.07M | -90.50M | -68.26M |
| Investing Cash Flow | -7.01M | -238.56M | 83.65M | 48.72M | 1.13M | 56.08M |
| Financing Cash Flow | 147.27M | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Capital Expenditure | -9.76M | -25.12M | -20.63M | -1.24M | -1.02M | -618.00K |
| Free Cash Flow | -45.21M | -85.93M | -125.05M | -103.31M | -91.53M | -68.88M |
| Share Buybacks | 1.00K | 13.00K | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 47.2% | -26.1% | -50.8% | -89.0% | -119.7% | -73.5% |
| ROCE % | -27.2% | -24.9% | -49.3% | -88.8% | -111.5% | -71.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.17% | 7.10M | $4.82M |
| 2 | Millennium Management Llc | 2.87% | 6.43M | $4.37M |
| 3 | Citadel Advisors Llc | 2.04% | 4.57M | $3.10M |
| 4 | Renaissance Technologies, LLC | 1.91% | 4.28M | $2.91M |
| 5 | Blackrock Inc. | 1.79% | 4.01M | $2.72M |
| 6 | Empery Asset Management, LP | 1.72% | 3.86M | $2.62M |
| 7 | Marshall Wace LLP | 1.56% | 3.50M | $2.38M |
| 8 | GSA Capital Partners LLP | 1.19% | 2.67M | $1.81M |
| 9 | Burkehill Global Management, LP | 0.89% | 2.00M | $1.36M |
| 10 | Geode Capital Management, LLC | 0.82% | 1.83M | $1.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNYA
A heart-disease biotech will meet investors at two September conferences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPbFJsMkc0a2VUdUs4MzV5eDRuQU9samRLb3JqZy10NkIxck1LWTV1MWtUUmg0SE9fdkpQU0piaWJIM3hodjF3OW9xY3dzNlpKTjdhM3J4QWFEdEg0WDVXRXV2OW9nQUNGOTRvX1UxU2N6bWp5a29XNi10QURjMWh1dHlxQUtQa2JtRnU2aV…
When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPcG5peERDUnRtX1BnemlfenZmdEZmWGo1Qzk5bFM0NnBTOFdpX3A4bjB6dDhVazF0cmxIZy03aXlFUFg5aHpOUXdkT2ZUclNjWE1SLXFNSDZlMnZWTFlDV3o5SlVRRXZSN3JfTVIxcVJ6NzgyT3BKQVFHOHNTNTBvWVYzOUZPbUZXNmlfcV…
Should I buy Tenaya Therapeutics (TNYA) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9kRUJfRFVMaHM0Z1ZaU0x0YzBFSjN5VW52N05EZnlJc3hybXNoaFdpeUV4ZXNrRXQ4eFd6cXRQemhSRkdNY0VWQW04ck1jQnc5LXBTTTRGMlpUWG9UVkQxb0VvVkhISzFXaEZvZQ?oc=5" target="_blank">Should I buy Tenaya T…
Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOcVRVM25qWVBQT1hPSzZjWXF5cjdSaHdOekgzbTdlVjJDQ3VnTkc1cXpqeGpOM200YXNtRDdXZ3J2LVRTVmptVmtIT2dVVW0yYzZTbEpOSlZzN0pkR04xUzF4RVpOWkliNmt0STVTX1NQb1hUNG9VSlNtRUtPRURuRldtMVdWSUVNR08xbn…
TNYA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBPbkc5eFhFTDNWZEpZTVVvLW9tV24zNjBzZ3Awb0p2bVdQS3pDRXJpWEl6XzR5dzJ3WkRmaVNUZDFUZW95dUE?oc=5" target="_blank">TNYA</a> <font color="#6f6f6f">Finviz</font>…
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Moomoo
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOU2NhZXNTaHE1akFMcFoyengwRUZ1eGJrTVB4S1NRTjZ3dFd1QUgxNVJaQVRCcHN3RV91NlpEdG9Tdmh1ekhMdzJDN1ItVU50cHh4Mk9weXR2ZnNCNU5EQ1hGcGtsQlE2Zm0zTzhvRHo1TVN4Uzc3WUxvc1hHMGQxU20tZG5tT0lJR09naT…
TNYA — Frequently Asked Questions
What is the current share price of Tenaya Therapeutics, Inc. (TNYA)?
As of 2026-09-19 21:16 PDT, Tenaya Therapeutics, Inc. (TNYA) trades at $0.66 on NasdaqCM. Its 52-week range is $0.55 to $2.10.
What is the market capitalisation of TNYA?
Tenaya Therapeutics, Inc. (TNYA) has a market capitalisation of $147.99M on NasdaqCM.
What is the P/E ratio of TNYA?
TNYA trades at a trailing price-to-earnings (P/E) ratio of -1.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.39.
What is the return on equity (ROE) of TNYA?
TNYA has a return on equity (ROE) of -121.86%. Its return on capital employed (ROCE) is -70.98%.
Is TNYA a good stock to buy?
This page provides a data-driven analysis of Tenaya Therapeutics, Inc. (TNYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.